Objectives: To evaluate the depth of transurethral resections of bladder tumour (TURBT), residual cancer rates and up-staging rates in a contemporary Australian series.
Materials And Methods: Specimen reports from a single, major reporting pathology centre, servicing a group of urological oncologists in Sydney were obtained for TURBTs performed between October 2008 and February 2013. We examined the depth of TURBT, rates of repeat-TURBT (re-TUR) and residual cancer rates at the 3-6 month check cystoscopy.
Results: One thousand and two hundred and nine transurethral resection specimens retrieved during this period were analysed. There were 162 (13.4%) T1 specimens and 631 (52.2%) Ta specimens, 218 (34.5%) of which were high grade. Muscularis propria was present in 506 (41.9%) specimens in total and in 151 (39.7%) of 380 high-risk specimens (high grade Ta, T1). Of the 380 high-risk non-muscle-invasive tumours, 85 (22.4%) proceeded to re-TUR. Of the 48 T1 specimens and 37 Ta high grade specimens that proceeded to re-TUR, 7 (14.6%) and 1 (2.7%) respectively were upstaged to muscle-invasive disease. Rates of residual disease/early recurrence at 3-6 months was significantly better for those with re-TUR compared to those without 56.8% vs 82.5% (P < 0.001) for Ta high grade and 39.6% vs 84% (P = 0.028) for T1 tumours respectively.
Conclusion: Re-TUR rates in high-risk non-muscle-invasive bladder cancer are low. However in a contemporary series, the upstaging rates are low, but residual cancer rates high, supporting the need for re-TUR in this population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/bju.13265 | DOI Listing |
Psychiatr Hung
January 2025
Rosszullétek speciális elme- és ideggyógyászati szakrendelô, Budapest, Hungary, E-mail:
Author analyses the process of care of somatic symptom disorder in the general medical practice with special concern to iatrogenic harms. In his opinion the latency of the patients' first appointment with a psychiatrist or clinical psychologist is caused by multiple factors. Patients do not have knowledge on the basic activities of central nervous system necessary to recognize the pathomechanism.
View Article and Find Full Text PDFArthroplast Today
February 2025
Department of Orthopaedic Surgery, Scripps Clinic, La Jolla, CA, USA.
Background: Total hip arthroplasty (THA) is generally considered a successful operation for patients with advanced hip arthritis. Hip abductor pathology can lead to diminished outcomes. The prevalence of hip abductor pathology in patients undergoing THA is not well described.
View Article and Find Full Text PDFHardwareX
March 2025
Molecular and Systems Pharmacology Program, Emory University, Atlanta, GA, USA.
High-performance liquid chromatography (HPLC) is an invaluable technique that has been used for many decades for the separation of various molecules. The reproducible collection of eluates from these systems has been significantly improved via its automation by fraction collection systems. Current commercially available fraction collectors are not easily customizable, incompatible with other platforms, and come with a large cost barrier making them inaccessible to many researchers.
View Article and Find Full Text PDFWorld J Gastroenterol
January 2025
Department of General Surgery, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin 300052, China.
Background: Regulator of G protein signaling (RGS) proteins participate in tumor formation and metastasis by acting on the α-subunit of heterotrimeric G proteins. The specific effect of RGS, particularly , on the progression of gastric cancer (GC) is not yet clear.
Aim: To explore the role and underlying mechanisms of action of in GC development.
J Immunother Precis Oncol
February 2025
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Introduction: Advanced penile squamous cell carcinoma (pSCC) is a rare and aggressive malignancy with a poor prognosis and an unmet need for biomarkers. We performed a retrospective evaluation of real-world efficacy, safety outcomes, and baseline inflammatory biomarkers in patients with advanced pSCC treated with immune checkpoint inhibitors (ICIs).
Methods: We performed a retrospective review of patients with advanced pSCC who received ICIs from 2012 to 2023 at the Winship Cancer Institute of Emory University in Atlanta, GA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!